ArticleJournal of clinical medicine2019
Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.American journal of clinical dermatology · 2025Pooled it
- Acute erythrodermic psoriasis complicated by systemic capillary leak syndrome following secukinumab therapy: a case report.Frontiers in immunology · 2026Article
- Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.Dermatology and therapy · 2025Article
- Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study.American journal of clinical dermatology · 2024Article
- Biologic anti-IL17 drugs in erythrodermic psoriasis.JAAD international · 2024Article
- Use of biologics in patients with psoriasis - A retrospective analysis based on real-world data.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Effectiveness, quality of life, and safety of secukinumab versus conventional systemic therapy in patients with erythrodermic psoriasis: a comparative study.Frontiers in medicine · 2024Article
- Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study.Dermatology and therapy · 2023Article
- Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.Clinical, cosmetic and investigational dermatology · 2023Review
- Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Rapamycin Alleviates 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Aggravated Dermatitis in Mice with Imiquimod-Induced Psoriasis-Like Dermatitis by Inducing Autophagy.International journal of molecular sciences · 2021Article
- Updates on the Treatment of Erythrodermic Psoriasis.Psoriasis (Auckland, N.Z.) · 2021Review
- Special Issue on Clinical Medicine for Healthcare and Sustainability.Journal of clinical medicine · 2020Article
- Review
- Gut microbiota and nutrient interactions with skin in psoriasis: A comprehensive review of animal and human studies.World journal of clinical cases · 2020Review
- Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report.Drug target insightsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 4 countries.
Funding
Abstract
Erythrodermic psoriasis (EP) is a dermatological emergency and its treatment with secukinumab is still controversial. Furthermore, no data exist regarding the prognostic value of drug abuse in such a condition. We performed a multi-center, international, retrospective study, enrolling a sample of EP patients (body surface area > 90%) who were treated with secukinumab (300 mg) during the study period from December 2015 to December 2018. Demographics and clinical data were collected. Drug abuses were screened and, specifically, smoking status (packages/year), cannabis use (application/week) and alcoholism-tested with the Alcohol Use Disorders Identification Test (AUDIT)-were assessed. All patients were followed for up to 52 weeks. We enrolled 13 EP patients, nine males, and four females, with a median age of 40 (28-52) years. Patients naïve to biologic therapy were 3/13. Regarding drug use, seven patients had a medium-high risk of alcohol addiction, three used cannabis weekly, and seven were smokers with a pack/year index of 295 (190-365). The response rate to secukinumab was 10/13 patients with a median time to clearance of three weeks (1.5-3). No recurrences were registered in the 52-week follow-up and a Psoriasis Area Severity Index (PASI) score of 90 was achieved. The entire cohort of non-responders (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.